Review



rabbit anti human ip 10  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Bio-Rad rabbit anti human ip 10
    Rabbit Anti Human Ip 10, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti human ip 10/product/Bio-Rad
    Average 92 stars, based on 4 article reviews
    rabbit anti human ip 10 - by Bioz Stars, 2026-03
    92/100 stars

    Images



    Similar Products

    rabbit anti human ip 10  (Bio-Rad)
    92
    Bio-Rad rabbit anti human ip 10
    Rabbit Anti Human Ip 10, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti human ip 10/product/Bio-Rad
    Average 92 stars, based on 1 article reviews
    rabbit anti human ip 10 - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    antibodies against ip 10  (Bio-Rad)
    92
    Bio-Rad antibodies against ip 10
    Antibodies Against Ip 10, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against ip 10/product/Bio-Rad
    Average 92 stars, based on 1 article reviews
    antibodies against ip 10 - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    polyclonal rabbit anti human cxcr3 antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology polyclonal rabbit anti human cxcr3 antibody
    CXCL10 and <t>CXCR3</t> membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Polyclonal Rabbit Anti Human Cxcr3 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit anti human cxcr3 antibody/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    polyclonal rabbit anti human cxcr3 antibody - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    ahp782  (Bio-Rad)
    92
    Bio-Rad ahp782
    CXCL10 and <t>CXCR3</t> membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.
    Ahp782, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ahp782/product/Bio-Rad
    Average 92 stars, based on 1 article reviews
    ahp782 - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: CXCL10 and CXCR3 membranous and cytoplasmic staining in colorectal tumors. (A) Low CXCL10 expression was demonstrated in 19/71 samples in the recurrence group (RG) and 36/72 samples in the non-recurrence group (NRG). (B) Strong CXCL10 expression was observed in 27/71 samples in the RG and 10/72 in the NRG. (C) Low CXCR3 expression was demonstrated in 21/71 samples in the RG and 48/72 in the NRG. (D) Strong CXCR3 expression was demonstrated in 12/71 samples in the RG and 2/72 in the NRG. (E) Low CXCL10 expression was demonstrated in 6/10 normal tissue samples. (F) Negative CXCR3 expression was demonstrated in 10/10 normal tissue samples.

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Staining, Expressing

    Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Immunostaining for CXCL10 and CXCR3 expression in normal and CRC tissues.

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Immunostaining, Expressing

    Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Immunostaining for CXCL10 and CXCR3 in colorectal cancer (negative expression samples are absent).

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Immunostaining, Expressing

    Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P<0.0001, log-rank test) and negative expression (n=60, P<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P<0.0001) and negative expression (P<0.0001); however, there was no significant difference between low and negative expression (P=0.184).

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Survival curve of CXCR3 expression. (A) Patients with strong expression (n=14) exhibited significantly shorter disease-free survival (DFS) compared with those with low expression (n=69, P<0.0001, log-rank test) and negative expression (n=60, P<0.0001, log-rank test); low vs. negative expression, P=0.012. (B) Patients with strong expression also exhibited significantly shorter overall survival (OS) compared with those with low expression (P<0.0001) and negative expression (P<0.0001); however, there was no significant difference between low and negative expression (P=0.184).

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Expressing

    Association between CXCL10/CXCR3 and prognosis

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Association between CXCL10/CXCR3 and prognosis

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Expressing

    Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.

    Journal: Molecular and Clinical Oncology

    Article Title: CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer

    doi: 10.3892/mco.2015.665

    Figure Lengend Snippet: Kaplan-Meier analysis of cancer-specific overall survival (OS) of relapsed patients with stage II colorectal cancer subdivided by the presence of inflammatory adhesions and CXCR3 expression (P<0.0001). Expression of CXCR3 (A) in cases without adhesions and (B) in cases with adhesions.

    Article Snippet: A polyclonal rabbit anti-human CXCL10 antibody (cat. no. (C-20) sc-6226; dilution, 1:120; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit anti-human CXCR3 antibody (cat. no. sc-101500; dilution, 1:200) were separately added to the sections following deparaffinization, hydration, antigen repair and endogenous peroxidase blocking.

    Techniques: Expressing